Aykan NF, Özatlı T. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol 2020; 11(2): 53-73 [PMID: 32133275 DOI: 10.5306/wjco.v11.i2.53]
Corresponding Author of This Article
Nuri Faruk Aykan, MD, Professor, Department of Medical Oncology, Istinye University Medical School, Bahcesehir Liv Hospital, Atatürk Bulvarı, No. 6, Istanbul 34510, Turkey. nfaruk@mac.com
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Feb 24, 2020; 11(2): 53-73 Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.53
Objective response rate assessment in oncology: Current situation and future expectations
Nuri Faruk Aykan, Tahsin Özatlı
Nuri Faruk Aykan, Tahsin Özatlı, Department of Medical Oncology, Istinye University Medical School, Bahcesehir Liv Hospital, Istanbul 34510, Turkey
Author contributions: Aykan NF and Özatlı T performed the literature search; and Aykan NF wrote the manuscript.
Conflict-of-interest statement: No potential conflicts of interest and no financial support are associated with this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Nuri Faruk Aykan, MD, Professor, Department of Medical Oncology, Istinye University Medical School, Bahcesehir Liv Hospital, Atatürk Bulvarı, No. 6, Istanbul 34510, Turkey. nfaruk@mac.com
Received: May 5, 2019 Peer-review started: May 8, 2019 First decision: October 23, 2019 Revised: November 5, 2019 Accepted: November 28, 2019 Article in press: November 28, 2019 Published online: February 24, 2020 Processing time: 297 Days and 18.6 Hours
Core Tip
Core tips: The tumor objective response rate is an important parameter in oncology. World Health Organization and Response Evaluation Criteria in Solid Tumors (RECIST) are anatomic response criteria developed mainly for cytotoxic chemotherapy. These criteria may not be optimal for biologic agents, some disease sites, and some regional therapies. Some alternatives of RECIST were developed, but RECIST v1.1 is validated in prospective studies, is widely accepted by regulatory agencies and has recently shown good performance for targeted cancer agents. The newest alternatives of RECIST are immune-specific response criteria for checkpoint inhibitors. Metabolic response assessments using positron emission tomography (PET) or PET/computed tomography may reflect the viability of cancer cells or functional changes that occur after anticancer treatments.
